TruScreen Group (TRU) H2 2025 earnings summary

Executive summary

• FY2025 saw continued global recognition and commercial progress, with key clinical trials completed and national guideline endorsements in China, Vietnam, and other countries.

• Strategic alliance with Hangzhou Dalton Bioscience expanded product offerings and distribution, notably entering the Indian market.

• WHO and UNITAID included the AI-enabled screening device in guidelines, supporting entry into new markets.

• Major screening programs launched in Vietnam and product registrations achieved in Uzbekistan and Mexico.

• $2.3 million raised post-year-end via private placement and $1.67 million via share purchase plan to support growth.

Financial highlights

• Sales declined 18.7% to $1.71 million and total revenue fell 15.7% to $2.11 million year-over-year.

• Net loss increased 9.4% to $2.24 million compared to the prior year.

• Cash outflow from operating activities rose 12.6% to $2.29 million; cash and equivalents dropped 86.6% to $365,473.

• Basic and diluted loss per share improved to (0.41) cents from (0.49) cents year-over-year.

Outlook and guidance

• Anticipates continued revenue growth in China, with expansion into six key provinces and private health sectors.

• Vietnam expected to become the second largest market in FY2026, with a five-year screening program underway.

• Strategic focus on emerging markets, leveraging AI technology and expanded HPV product portfolio.